Skip to main content
< Back to news
 28.10.2025

Nuage Therapeutics strengthens its leadership in innovative therapies against IDPs thanks to the support of the Torres Quevedo program

Nuage Therapeutics, a spinoff of the Institute for Research in Biomedicine (IRB Barcelona) based at the Barcelona Science Park, has successfully completed two projects funded through the Torres Quevedo Program (PTQ2021-011961 and PTQ2021-011994), consolidating its innovative role in the discovery of new drugs targeting therapeutic targets traditionally considered intractable, such as intrinsically disordered proteins (IDPs), which are associated with serious diseases like cancer and have so far remained beyond the reach of conventional treatments.

The completed projects have focused on the development of a new approach to drug discovery, enabling the targeting of intrinsically disordered proteins (IDPs) and giving rise to a new generation of transformative therapies. IDPs are a class of proteins that for a long time were considered inaccessible to drugs. This advance opens the door to revolutionary therapeutic solutions.

Currently, Nuage Therapeutics is applying this innovative approach to address transcription factors that drive the growth of certain types of cancer, offering a revolutionary strategy for the treatment of specific tumors.

The execution of these projects has had a positive impact on the company’s growth and trajectory, achieving several notable milestones. Among them, the attraction of international investment stands out: Sofinnova Partners, one of Europe’s most prestigious venture capital firms in the biotechnology sector, has joined Nuage, marking a significant step in the company’s growth and expansion.

In addition, Nuage has strengthened its presence in competitive R&D programs, both nationally and at the European level. The company has been awarded highly selective grants, including the Public-Private Collaboration Projects of the AEI and Eurostars 2025. These collaborations not only reinforce public-private partnerships but also promote the internationalization of Nuage’s research and development activities.

Finally, the company has achieved significant advances in its research pipeline. Nuage’s proprietary technology has demonstrated efficacy against new intrinsically disordered proteins (IDPs), such as ASCL1, KLF5, and SOX2, highlighting the platform’s potential to address a broader range of therapeutic needs and consolidating its position as a leader in innovative therapies.

The Torres Quevedo Program is awarded by the State Research Agency (AEI) within the framework of the 2021-2023 State Plan for Scientific, Technical, and Innovation Research.

» Link to the news: Nuage Therapeutics website [+]